GZMB and neoplasm: Up-to-date radionuclide-, fluorescence-, nanoparticle-labeled mHsp70-targeted tools (including full recombinant Hsp70, monoclonal anti-Hsp70 antibodies, antibody Fab fragments, tumor penetrating peptide (TPP), granzyme B, and anticalines) have been successfully employed for visualization (MRI, PET, epifluorescence) and therapy in preclinical studies (Table 1).